Although [18F]fluorodeoxyglucose (FDG) generally shows an excellent performance as a cancer-imaging agent when using PET-CT, there are some settings in which other radiopharmaceuticals offer advantages. Such non-FDG tracers are now gaining widespread acceptance not only in research but also in clinical practice. This atlas, including about 500 high-quality images, is a user-friendly guide to PET-CT imaging beyond FDG. A wide range of tracers is covered, such as 18F- and 11C-choline, 11C-methionine, 18F-ethyl-L-tyrosine, 68Ga-DOTA-NOC, 11C-acetate, 11C-thymidine, and 18F-DOPA. Throughout, the emphasis is on image interpretation, with guidance on the recognition of normal, benign, and malignant uptake and clear instruction on learning points and pitfalls. This atlas is designed to serve as a reference text for both nuclear physicians and radiologists, and will also be of great benefit to radiographers, technologists, and nuclear medicine and radiology residents.

PET-CT is increasingly being employed in the diagnosis of both oncological and non-oncological patients, yet nuclear medicine physicians may have only limited practical experience of rare diseases and may experience difficulty in recognizing and interpreting rare findings. This unique atlas documents a large number of clinical cases that will help practitioners to identify findings and diseases that, though rare, are sufficiently frequent to be encountered in routine practice. Two types of cases are presented: patients evaluated for rare diseases and patients evaluated for standard diseases in whom atypical PET findings were detected. Each reported case includes a brief description of the clinical history, representative color PET-CT images obtained using FDG or other tracers, and a short explanation of the disease and findings. This atlas will enable practitioners to make conclusive reports of PET-CT scans that would otherwise have been inconclusive.

This issue of PET Clinics examines PET/CT Imaging in Tracers Beyond FDG. Article include standardization and quantification in PET/CT imaging: tracers beyond FDG; 18F NaF PET/CT imaging; 18F NaF PET/CT imaging in pediatrics; choline PET/CT imaging for the head and neck, thorax, abdomen, and pelvis; DOPA PET/CT imaging for the head and neck, thorax, abdomen, and pelvis; 68 GaSSRTs PET/CT imaging for the head and neck, thorax, abdomen, and pelvis; FLT PET/CT imaging for the head and neck, thorax, abdomen, and pelvis; hypoxia tracers; PET/MRI tracers beyond FDG: current status and future aspects; PET/CT normal variations: effect of novel quantitative approaches; and more!

This pocket book explains the significant and well-documented impact that PET/CT can have on the management of prostate cancer through the provision of high-quality evidence regarding function and structure. Up-to-date information is supplied on the relevance of PET/CT to diagnosis, treatment planning, and therapy, including the emerging role of PET/CT with PSMA. Readers will also find clear explanation of the relation of the clinical and pathological background to imaging and the value of PET/CT compared with conventional radiological imaging. The book will be an excellent asset for referring clinicians, nuclear medicine/radiology physicians, radiographers/technologists, and nurses who routinely work in nuclear medicine and participate in multidisciplinary meetings. It is published within the Springer series Clinicians’ Guides to Radionuclide Hybrid Imaging, which presents contributions from professionals worldwide who share a common purpose in promoting nuclear medicine as an important imaging specialty for the diagnosis and management of oncological and non-oncological conditions.

This is a comprehensive guide for patient preparation, image acquisition, and image interpretation for PET/CT and PET/MR, specifically relevant to melanoma and sarcoma. Imaging specialists and referring physicians are often not as intimately aware of the particulars of PET imaging in management of patients with melanoma and sarcoma and how it could affect their treatment. This book fills that gap by presenting comprehensive information on melanoma, sarcoma, and the role of PET imaging in their diagnosis and management. The book begins by covering the basics of imaging for practicing physicians and trainees. Expert authors then further cover the biological concepts of melanoma and sarcoma and how they relate to imaging, particularly PET, the oncologist’s perspective, and the surgeon’s perspective on imaging for both the imaging specialist and the referring physician. Chapters review topics such as: PET/CT and PET/MR images in melanoma and sarcoma from a systemic approach, false-positives, false-negatives, pitfalls, and molecular imaging beyond PET. Images are used extensively throughout to enhance understanding for the reader. This is an ideal guide for radiologists, nuclear medicine physicians, oncologists, surgeons, trainees and technologists.

Fluorodeoxyglucose (FDG) has proven benefits as a positron emission tomography (PET) radiopharmaceutical in oncology.

PET and PET-CT in Oncology describes the principles of positron emission tomography and is a useful resource for incorporating the technique in clinical practice. In a clear and straightforward fashion, the book offers instructive information and overviews of the basic principles of PET and PET-CT as well as the routine clinical PET scanning procedures for all important oncological indications. It is designed to serve as a reference work for specialists in nuclear medicine and radiology (including therapy planning) and for oncologists. It also provides student and physicians in other medical specialities with a general introduction to the effective integration of this modern technique into routine clinical diagnostics. Above all, this volume illustrates the importance of PET and PET-CT in comparison with other imaging techniques.